AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
"In the period 1821–1822, the liberator José de San Martín and Bernardo Monteagudo, his trusted minister, expropriated and squandered the mercantile and economic elite of Lima, without achieving the definitive independence of Peru. Monteagudo had little regard for the level of civilization and the democratic possibilities of Peruvians. His main objective was to eradicate the Spanish threat in independent La Plata and Chile at any cost, including the economic ruin of Peru. He confiscated wealth and other resources to organize local spy networks and covert operations, clearly damaging to gaining the confidence of the local population and their support for the cause of independence. (…) The kidnapping policy inaugurated by Monteagudo further undermined a weak tradition of the right to property and laid the foundations for politically motivated expropriations. The agricultural and urban properties confiscated from royalist Spaniards and Creoles, mainly in the central coast region, were valued at approximately two million pesos. This policy caused greater economic problems and a drop in investment. (...) Eventually, most of the expropriated assets were awarded to military officers who sought compensation and rewards for their patriotic exploits. Among the high-ranking officers who received these rewards we have Antonio José de Sucre, Bernardo O'Higgins, and José Rufino Echenique. Juan Francisco Ryes, Blas Sardeña and José María Plaza, among others. In the provinces, local officials repeated the abuses of power and the plundering committed in the name of the patriot cause.
In the late 1960s, Torbjörn Caspersson developed a quinacrine fluorescent staining technique (Q-banding) which revealed unique banding patterns for each chromosome pair. This allowed chromosome pairs of otherwise equal size to be differentiated by distinct horizontal banding patterns. Banding patterns are now used to elucidate the breakpoints and constituent chromosomes involved in chromosome translocations. Deletions and inversions within an individual chromosome can also be identified and described more precisely using standardized banding nomenclature. G-banding (utilizing trypsin and Giemsa/ Wright stain) was concurrently developed in the early 1970s and allows visualization of banding patterns using a bright field microscope. Diagrams identifying the chromosomes based on the banding patterns are known as idiograms. These maps became the basis for both prenatal and oncological fields to quickly move cytogenetics into the clinical lab where karyotyping allowed scientists to look for chromosomal alterations. Techniques were expanded to allow for culture of free amniocytes recovered from amniotic fluid, and elongation techniques for all culture types that allow for higher-resolution banding.
==== Anxiety disorders ==== Tiagabine may be prescribed off-label to treat certain anxiety disorders, such as panic disorder and social anxiety disorder. Tiagabine may be used alongside selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), or benzodiazepines for anxiety. The drug was ineffective for generalized anxiety disorder.
Sources: en.wikipedia.org
Each component in the sample interacts differently with the adsorbent material and the solvents, so their rates of elution are different. These different rates lead to analytical separation of the species in the fluid that flows out of the column (the eluate). The eluate enters a specific chromatography detector such as UV detectors, which produces a graph (the chromatogram). A chromatogram is a graph of detector signal intensity versus time or the volume of the mobile phase. If the analytes are well-separated, then the chromatogram would show well-separated peaks, one per analyte. Each analyte appears in its respective time (retention time) having area proportional to its amount. Chromatography can be described as a mass transfer process involving adsorption and/or partition. As mentioned, HPLC relies on pumps to pass a pressurized liquid and a sample mixture through a column filled with the adsorbent (the active component of the column). Some analytes may strongly attach to the adsorbent rather than the eluent, while other analytes may do the opposite. That is, the analytes may have different partition coefficients, leading to the separation of the analytes. The interaction between the analyte, the solid phase, and the liquid phase, are physical or chemically reversible, usually a combination of non-covalent interactions.
After drug withdrawal, the effects fade away slowly, but may persist for more than 6–12 weeks after cessation of AAS use. Strength improvements in the range of 5 to 20% of baseline strength, depending largely on the drugs and dose used as well as the administration period. Overall, the exercise where the most significant improvements were observed is the bench press. For almost two decades, it was assumed that AAS exerted significant effects only in experienced strength athletes. A randomized controlled trial demonstrated, however, that even in novice athletes a 10-week strength training program accompanied by testosterone enanthate at 600 mg/week may improve strength more than training alone does. This dose is sufficient to significantly improve lean muscle mass relative to placebo even in subjects that did not exercise at all. The anabolic effects of testosterone enanthate were highly dose dependent.
Unlike reference materials, working standards are typically not calibrated across multiple analytical facilities and the accepted δ value measured in a given laboratory could reflect bias specific to a single instrument. However, within a single analytical facility this bias can be removed during data reduction. Because each laboratory defines unique working standards the primary, calibration, and reference materials are long-lived while still ensuring that the isotopic composition of unknown samples can be compared across laboratories.
Sources: en.wikipedia.org
"The fibrous variant of Hashimoto's thyroiditis" (1974, with Austin L. Vickery Jr.) "Thymoma in a 12-year-old boy" (1976, with Jane Chatten) "Urinary Ultrastructural Findings in Fabry Disease" (1977, with Patricia J. Lyons) "Examination of Sputum in Legionnaire's Disease" (1978) "Legionnaires' disease: structural characteristics of the organism" (1978, with Philip Nash) "Leydig cell tumors of the testis" (1979, with I. Damjanov and M. A. Jewett) "Ultrastructural Features of Respiratory Cilia in Cystic Fibrosis" (1980, with Douglas S. Holsclaw Jr.) "Postinflammatory pseudotumors of the lung: fibrous histiocytoma and related lesions" (1980, with E. E. Schwartz and G. A. Mandell) "Tolmetin: Association With Reversible Renal Failure and Acute Interstitial Nephritis" (1981, with Ralph Capaldo, Erich A. Everts, and John G. DiGregorio) "Pleomorphism of Legionella pneumophila" (1984, with Shahab Hashemi, Kristy R. Brown, William A. Habib, and Jay M. Hammel) "Cilia in the Human Kidney" (1984, with Joseph J. Morgan) Legionellosis (1985) "Microscopic Nephrocalcinosis in Cystic Fibrosis" (1988, with Leslie J. Krueger and Bonita L. Falkner) "A Self-Limited Febrile Illness Produced in Guinea Pigs Associated With Oral Administration of Legionella pneumophila" (1988, with Jay M. Hammel, Joseph P. Matus, Ronald Poropatich, and Julian Katz) "Diagnostic value of electron microscopy on paraffin-embedded cytologic material" (1993, with Nancy A. Young and Sonya Naryshkin)
Chloroformic acid is a chemical compound with the formula ClCO2H. It is the single acyl-halide derivative of carbonic acid (phosgene is the double acyl-halide derivative). Chloroformic acid is also structurally related to formic acid, in a way that the non-acidic hydrogen of formic acid is replaced by chlorine. Despite the similar name, it is very different from chloroform. It is described as unstable, decomposing into carbon dioxide and hydrogen chloride. Chloroformic acid itself is too unstable to be handled for chemical reactions. However, many esters of this carboxylic acid are stable and these chloroformates are important reagents in organic chemistry. They are used to prepare mixed carboxylic acid anhydrides used in peptide synthesis.
=== Other names === Alternate spellings include fenibut and phenybut. It is also sometimes referred to as aminophenylbutyric acid. The word phenibut is a contraction of the chemical name of the drug, β-phenyl-γ-aminobutyric acid. In early publications, phenibut was referred to as fenigam and phenigama. The drug has not been assigned an INNTooltip International Nonproprietary Name.
He earlier announced that his administration would not deport unaccompanied migrant children; the rise in arrivals of such children exceeded the capacity of facilities meant to shelter them, leading the Biden administration in March to direct the Federal Emergency Management Agency to help. On April 14, Biden announced that the United States would delay the withdrawal of all troops from the war in Afghanistan until September 11, signaling an end to the country's direct military involvement in Afghanistan after nearly 20 years. In February 2020, the Trump administration had made a deal with the Taliban to completely withdraw U.S. forces by May 1, 2021. Biden's decision met with a range of reactions, from support and relief to trepidation at the possible collapse of the Afghan government without American support. On April 22–23, Biden held an international climate summit at which he announced that the U.S. would cut its greenhouse gas emissions by 50%–52% by 2030 compared to 2005 levels. On April 28, the eve of his 100th day in office, Biden delivered his first address to a joint session of Congress.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.